Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RelabotulinumtoxinA for Moderate to Severe Glabellar Lines
NCT04249583Phase 3Completed
- Sponsor
- Galderma
- Start
- Feb 2020
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of relabotulinumtoxinA in glabellar lines, sponsored by Galderma. Started Feb 2020; status: completed.
02
Drugs
relabotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT04249583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249583.